GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Hangzhou Tigermed Consulting Co Ltd (SZSE:300347) » Definitions » EBIT

Hangzhou Tigermed Consulting Co (SZSE:300347) EBIT : ¥2,523 Mil (TTM As of Mar. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Hangzhou Tigermed Consulting Co EBIT?

Hangzhou Tigermed Consulting Co's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was ¥348 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was ¥2,523 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Hangzhou Tigermed Consulting Co's annualized ROC % for the quarter that ended in Mar. 2024 was 5.52%. Hangzhou Tigermed Consulting Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 93.67%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Hangzhou Tigermed Consulting Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 6.16%.


Hangzhou Tigermed Consulting Co EBIT Historical Data

The historical data trend for Hangzhou Tigermed Consulting Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hangzhou Tigermed Consulting Co EBIT Chart

Hangzhou Tigermed Consulting Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,129.57 2,269.49 3,709.48 2,668.56 2,608.43

Hangzhou Tigermed Consulting Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 433.47 1,218.49 -238.83 1,195.30 348.37

Competitive Comparison of Hangzhou Tigermed Consulting Co's EBIT

For the Diagnostics & Research subindustry, Hangzhou Tigermed Consulting Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hangzhou Tigermed Consulting Co's EV-to-EBIT Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Hangzhou Tigermed Consulting Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Hangzhou Tigermed Consulting Co's EV-to-EBIT falls into.



Hangzhou Tigermed Consulting Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥2,523 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hangzhou Tigermed Consulting Co  (SZSE:300347) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Hangzhou Tigermed Consulting Co's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=1393.464 * ( 1 - 13.74% )/( (21568.617 + 22001.915)/ 2 )
=1202.0020464/21785.266
=5.52 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=29680.742 - 906.72 - ( 7462.13 - max(0, 4138.736 - 11344.141+7462.13))
=21568.617

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=30070.185 - 870.513 - ( 7450.213 - max(0, 4463.914 - 11661.671+7450.213))
=22001.915

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Hangzhou Tigermed Consulting Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=1393.464/( ( (1472.608 + max(-167.664, 0)) + (1502.672 + max(-292.668, 0)) )/ 2 )
=1393.464/( ( 1472.608 + 1502.672 )/ 2 )
=1393.464/1487.64
=93.67 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1260.7 + 23.398 + 153.685) - (906.72 + 0 + 698.727)
=-167.664

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1209.165 + 23.674 + 132.474) - (870.513 + 0 + 787.468)
=-292.668

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Hangzhou Tigermed Consulting Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2024 )
=2523.323/40938.611
=6.16 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hangzhou Tigermed Consulting Co EBIT Related Terms

Thank you for viewing the detailed overview of Hangzhou Tigermed Consulting Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Hangzhou Tigermed Consulting Co (SZSE:300347) Business Description

Traded in Other Exchanges
Address
Block 8, No. 19 Jugong Road, Room 2001-2010, 20th Floor, Xixing Sub-District, Binjiang District, Hangzhou, CHN, 310053
Hangzhou Tigermed Consulting Co Ltd is a China-based Contract Research Organization. The company's segment includes Clinical trial solutions and Clinical-related and laboratory services. It generates maximum revenue from the Clinical trial solutions segment. The company's offered services include bioanalytical, medical writing, biostatistics analysis, and medical imaging. The therapeutic areas of the company include Infections, Hematology, Cardiovascular, Endocrinology, Rheumatology, Nephrology, and Central Nervous System (CNS) among others.
Executives
Directors, executives
Cao Xiao Chun Directors, executives
Executives
Ye Xiao Ping Director
Shi Xiao Li Supervisors
Wang Xiao Bo Supervisors
Li Xiao Ri Securities Affairs Representative
Xu Jia Lian Executives
Gong Yan Hua Director

Hangzhou Tigermed Consulting Co (SZSE:300347) Headlines

No Headlines